From London to São Paulo: Avenues Bets AI Can Scale the Business of IVF

LONDON and SÃO PAULO – July 06, 2026 – In the high-stakes, deeply personal world of fertility treatment, scale is a difficult mountain to climb. Most successful clinics are built over decades, growing their reputation patient by patient. Avenues, a London-based fertility provider, is attempting to rewrite that playbook. Just two years after opening its doors, the company has announced its first international expansion into Brazil, a move that signals a bold bet on a new business model for reproductive medicine: one driven by artificial intelligence, robotics, and a blueprint designed for rapid global replication.

The launch of Avenues Brazil in São Paulo, through a strategic partnership with four of the country's leading fertility specialists, isn't just another clinic opening. It's the first major test of a hypothesis that could disrupt the multi-billion dollar global fertility market: that the efficiency of an AI-native operating system can be paired with compassionate care to deliver a superior, and supremely scalable, product.

The Anatomy of Unprecedented Growth

To understand the significance of the move into Latin America, one must first look at Avenues' trajectory in the UK. Founded in January 2024 by Dr. Cristina Hickman, a veteran who has built 13 IVF clinics, Avenues claims to be the UK's fastest-growing fertility provider. The numbers are, on their face, staggering. The company reports a year-on-year growth rate exceeding 227% and is now performing over 2,000 egg collections annually. This volume places it among the UK's largest private clinics—a status most rivals have taken decades to achieve.

This aggressive scaling is a core part of the business strategy. While the press release touts these figures, it's important to note that as a clinic less than two years old, its performance data has yet to be independently verified by the Human Fertilisation & Embryology Authority (HFEA), the UK’s regulator. However, the velocity is undeniable. A second UK clinic is already slated to open in Cambridge this autumn, underscoring the replicable nature of its model.

The company's rise is happening against the backdrop of a booming market. The UK fertility sector is projected to grow at a compound annual rate of 8.7% through 2030, fueled by demographic shifts and technological advancements. Avenues is not just riding this wave; it is attempting to steer it with a fundamentally different operational structure.

The Engine Room: An AI-Native Operating System

At the heart of Avenues' model is not a single piece of technology, but a fully integrated, digital-first ecosystem. Unlike established clinics that may retrofit AI tools onto existing workflows, Avenues was purpose-built around a platform designed to capture more clinical and operational data than any competitor. This data is the fuel for its AI engine.

"Our ambition was never to build one exceptional clinic," said Dr. Cristina Hickman, Founder of Avenues. "It was to build a model capable of bringing exceptional fertility care to millions more people."

This model translates into tangible operational advantages. The clinic employs a suite of AI tools across the patient journey. Its 'Reproductive Intelligence Review' uses AI to assess everything from hormones to lifestyle factors. In the lab, 'Embryo Intelligence' draws on data from millions of embryos to help embryologists predict viability, while 'Semen Intelligence' analyzes and ranks sperm to optimize selection for ICSI procedures. Even cryostorage is automated, using the TMRW robotic system—the only one of its kind in London—to digitally track and monitor frozen eggs and embryos, eliminating the risk of manual errors.

The business logic is clear: AI and automation reduce administrative burdens, optimize lab workflows, and standardize processes. This efficiency is the key to the company's modular clinic design, which allows for rapid setup of new locations while maintaining identical clinical standards. The goal is to create a franchise-like consistency, ensuring that the quality of care in São Paulo mirrors that of London.

A Strategic Gamble on the Brazilian Market

The choice of Brazil for its first international venture is a calculated one. The country is a recognized leader in reproductive medicine, boasting a deep pool of clinical talent and a history of scientific innovation. Rather than entering as an outside disruptor, Avenues has opted for a partnership model, joining forces with four highly respected local figures: reproductive scientist Dr. Edson Lo Turco, embryologist and executive Bernardo Lamounier de Moura, physician Dr. Luis Balducci, and CEO Fernando Prado Ferreira.

This approach mitigates risk by embedding the Avenues platform within a framework of established local expertise. The Brazilian partners bring market knowledge, clinical credibility, and the ability to navigate the local regulatory landscape. Avenues brings the technology and the scalable operating system.

"Brazil has some of the world's finest reproductive specialists," stated Fernando Prado Ferreira, one of the Brazilian partners. "Avenues has developed one of the world's most advanced fertility platforms. Bringing those strengths together gives us an extraordinary opportunity... to redefine what patients should expect from fertility care."

This move positions Avenues Brazil to become one of Latin America's most technologically advanced fertility centers. It's a classic 'think global, act local' strategy, leveraging a standardized tech stack while relying on local leadership for execution and patient trust. If successful, it will provide a powerful proof of concept for further expansion into other markets.

Balancing The Algorithm and The Human Touch

For all its focus on technology and efficiency, Avenues insists its ultimate goal is to amplify, not replace, the human element of care. The central promise is that by automating administrative and repetitive tasks, clinicians are freed up to spend more quality time with patients.

"Technology should never replace compassion, it should amplify it," Dr. Hickman noted. "By removing inefficiencies, giving clinicians better information and creating a truly connected patient journey, we can deliver better care, better outcomes and make fertility treatment more accessible."

This is the critical balancing act at the core of the company's brand and, potentially, its long-term success. The fertility journey is an emotional and psychological marathon, and patients consistently rank compassionate support as a top priority. Avenues addresses this through a patient app that streamlines communication and dedicated patient coordinators.

However, the heavy reliance on AI in such a sensitive field is not without its challenges and ethical questions. Issues of data privacy, algorithmic transparency, and potential bias are paramount. The 'black box' nature of some AI decision-making can be unsettling for patients who want to understand every aspect of their treatment. Regulatory bodies like the HFEA are already grappling with how to oversee a sector that is becoming increasingly technology-driven.

Dr. Hickman addresses this head-on: "This is not about replacing people with technology. It is about giving exceptional clinicians the tools they need to spend more time caring for patients while intelligent systems continuously improve every part of the patient journey."

Avenues' venture is more than just a story of a fast-growing startup. It represents a potential paradigm shift in how specialized medical services are delivered. The expansion into Brazil is the first real-world test of whether this AI-powered, meticulously designed model can be successfully exported. The global fertility industry will be watching closely to see if Avenues has truly cracked the code for scaling both the bottom line and the human touch.